1 es in patients with BAD after treatment with colesevelam.

2 s to assess the effect of cholestyramine and colesevelam.

3 ial GLP-1 concentrations were not altered by Colesevelam.

4 , 95% CI 0.70-1.02; P=0.07; N=3806), whereas colesevelam 3.75 g/d was associated with a reduction in

5 proven NASH were randomly assigned to either colesevelam 3.75 g/day orally or placebo for 24 weeks.

6 changed, integrated Meal Ra was decreased by Colesevelam (5,191 +/- 204 vs. 5,817 +/- 204 mumol/kg/6

7       Therefore, we examined the efficacy of colesevelam, a potent BAS, to decrease liver fat in pati

8 nts with a positive SeHCAT were treated with colesevelam and dosing was titrated to symptomatic respo

9 of 4.9% (P = 0.014) in liver fat between the colesevelam and the placebo arms.

10  cholestasis with the bile salt sequestrant, colesevelam, but not placebo, effectively reduced total

11 ration approval of the bile acid sequestrant colesevelam HCl for reducing glycemia in patients with T

12                       Compared with placebo, colesevelam increased liver fat by MRI-PDFF in all nine

13 reover, treatment of ob/ob mice with the BAS colesevelam increases intestinal proglucagon gene expres

14                                              Colesevelam increases liver fat in patients with NASH as

15      To do so, we tested the hypothesis that Colesevelam increases the disposition index (DI), and th

16 e the effect of bile acid sequestration with Colesevelam on fasting and postprandial glucose metaboli

17 ts were studied before and after 12 weeks of Colesevelam or placebo using a labeled triple-tracer mix

18                                 Therapy with Colesevelam was associated with a decrease in fasting (7

19 of 0.63 (95% CI 0.52-0.77; P=6.3x10(-6)) and colesevelam with an odds ratio of 0.64 (95% CI 0.52-0.79